Epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) is an
important subtype of lung cancer. With the existing and ongoing research and multiple …

Anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer (NSCLC)
comprises a distinct molecular entity with a reported global prevalence of 5–7%. The …

Lung cancer varies between Caucasians and Asians. There have been differences recorded
in the epidemiology, genomics, standard therapies and outcomes, with variations according …

Anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is a
molecularly distinct subgroup of oncogene-addicted NSCLC, accounting for 3-5% of cases …

The journey of a thousand miles in lung cancer therapy began with the discovery of
actionable genomic alterations. The two most well described molecular alterations are the …

DISCUSSION Introduction to EGFR EGFR belongs to the erythroblastic leukemia viral
oncogene homolog (ERBB) family of receptor tyrosine kinases and is alternatively known as …

In the quest to improve the diagnosis and treatment of non-small-cell lung carcinoma
(NSCLC), particularly in cases involving anaplastic lymphoma kinase (ALK) gene …

Figure 1: The left panel shows the liver lesion while the right panel shows the lung window
of the scans at different time points.(a and b) The baseline imaging prior to starting …

Introduction The outcomes in advanced NSCLC have improved owing to the availability of
more effective systemic and improved supportive care. This has increased the number of …

Background: Accurate molecular testing in non-small-cell lung cancer (NSCLC) is of
paramount importance for treatment, prediction, and prognostication. Objectives: We aimed …